39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer

彭布罗利珠单抗 伦瓦提尼 医学 肿瘤科 化疗 内科学 子宫内膜癌 妇科 癌症 免疫疗法 甲状腺癌
作者
S. Pignata,C Marth,R.G. Moore,Mariusz Bidziński,Asude Ayhan,María Jesús Rubio Pérez,Mario Beiner,Marcia Hall,Christof Vulsteke,Elena Ioana Braicu,Kenzo Sonoda,Xiang Wu,S. Frentzas,André Mattar,J. McKenzie,Lan Yao,Vivek Khemka,Lucy Gilbert,V. Makker
出处
期刊:ESMO open [Elsevier BV]
卷期号:9: 103539-103539
标识
DOI:10.1016/j.esmoop.2024.103539
摘要

LEN/PEMBRO following prior systemic therapy in any setting, including neo/adjuvant, is a standard of care for advanced endometrial cancer (EC). The phase 3 ENGOT-en9/LEAP-001 trial (NCT03884101) compared 1L LEN/PEMBRO vs chemo in patients (pts) with advanced/recurrent EC. Eligible pts had stage III–IV or recurrent, measurable/non-measurable, radiographically apparent EC, with no prior chemo or PD ≥6 mo after neo/adjuvant platinum-based chemo. Pts were randomized 1:1 (stratified by proficient vs deficient mismatch repair status [pMMR/dMMR] and, in the pMMR stratum, by ECOG PS [0/1], measurable disease [yes/no], and chemo/chemoradiation [yes/no]) to lenvatinib 20 mg QD plus pembrolizumab 200 mg Q3W or paclitaxel 175 mg/m2 Q3W plus carboplatin AUC 6 Q3W. Dual primary endpoints were PFS (RECIST v1.1, blinded independent central review) and OS in the pMMR population and among all-comers. Secondary endpoints included ORR and safety; duration of response (DOR) was an exploratory endpoint; and efficacy outcomes assessed by tumor histology was a prespecified exploratory analysis. 842 pts were randomized. At final analysis (data cutoff, 2 Oct 2023), after median follow-up of 38.4 (range, 30.3–52.9) mo, statistical significance for noninferiority (NI) OS endpoint was not achieved for LEN/PEMBRO vs chemo in the pMMR population (HR, 1.02 [95% CI, 0.83–1.26]; NI P = 0.2459875; Table). PFS and OS results for LEN/PEMBRO vs chemo by histological subtype will be presented for the pMMR population and all-comers. Treatment-related AEs occurred in 411/420 (97.9%) vs 398/411 (96.8%) treated pts in the LEN/PEMBRO vs chemo groups.Table: 39MOpMMRAll-comersLEN/PEMBRO n = 320Chemo n = 322LEN/PEMBRO n = 420Chemo n = 422OS HR (95% CI)1.02 (0.83–1.26)a0.93 (0.77–1.12)PFS HR (95% CI)0.99 (0.82–1.21)0.91 (0.76–1.09)ORR (95% CI), %50.6 (45.0–56.2)54.7 (49.0–60.2)55.7 (50.8–60.5)55.5 (50.6–60.3)Median DOR (range), mo16.1 (1.0+ to 48.7+)10.6 (1.1+ to 43.8+)23.2 (1.0+ to 49.0+)10.9 (1.1+ to 46.9+)a1-sided NI P = 0.2459875 (nonsignificant), not crossing prespecified OS NI boundary, P = 0.0158890, so no further statistical testing of efficacy endpoints was performed per prespecified multiplicity strategy for type 1 error control. Open table in a new tab a1-sided NI P = 0.2459875 (nonsignificant), not crossing prespecified OS NI boundary, P = 0.0158890, so no further statistical testing of efficacy endpoints was performed per prespecified multiplicity strategy for type 1 error control. The prespecified statistical criteria for OS and PFS in pts with pMMR IL advanced/recurrent EC were not met. Subgroup analyses identifying pts who may benefit most from LEN/PEMBRO will be presented. The safety profile was manageable and consistent with prior experience.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dktrrrr完成签到,获得积分10
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
丘比特应助科研通管家采纳,获得20
1秒前
1秒前
ccc完成签到,获得积分10
6秒前
萧秋灵完成签到,获得积分10
7秒前
缓慢冥幽完成签到,获得积分10
7秒前
旺仔同学完成签到,获得积分10
16秒前
吉以寒完成签到,获得积分10
22秒前
科研老兵完成签到,获得积分10
24秒前
量子星尘发布了新的文献求助10
27秒前
fys131415完成签到 ,获得积分10
42秒前
执着的忆雪完成签到 ,获得积分10
45秒前
47秒前
闵不悔完成签到,获得积分10
59秒前
阳光火车完成签到 ,获得积分10
1分钟前
cc完成签到,获得积分10
1分钟前
合适的寄灵完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
科研通AI5应助cc采纳,获得10
1分钟前
铜泰妍完成签到 ,获得积分10
1分钟前
贝贝完成签到 ,获得积分10
1分钟前
Lrcx完成签到 ,获得积分10
1分钟前
Wen完成签到 ,获得积分10
1分钟前
盘尼西林完成签到 ,获得积分10
1分钟前
LOVE0077完成签到,获得积分10
1分钟前
zhao完成签到,获得积分10
1分钟前
BINBIN完成签到 ,获得积分10
1分钟前
ambrose37完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
fufufu123完成签到 ,获得积分10
1分钟前
开心的大娘完成签到,获得积分10
1分钟前
www完成签到 ,获得积分10
1分钟前
末末完成签到 ,获得积分10
1分钟前
无为完成签到 ,获得积分10
1分钟前
白嫖论文完成签到 ,获得积分10
1分钟前
上官若男应助忧伤的步美采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
2分钟前
从心随缘完成签到 ,获得积分10
2分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022